Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Britain Courts Anthropic Amid US Defense Department Dispute 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
 - EconoTimes)
NEW ORLEANS, July 28, 2017 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 29, 2017 to file lead plaintiff applications in a securities class action lawsuit against Allergan, Inc. (NYSE:AGN), if they sold call options, purchased put options and/or sold equity forward contracts of the Company between February 25, 2014 and April 21, 2014, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
What You May Do
If you sold call options, purchased put options and/or sold equity forward contracts of Allergan and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit http://ksfcounsel.com/cases/nyse-agn to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 29, 2017.
About the Lawsuit
Allergan and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The Complaint asserts claims under Sections 14(e), 20A and 20(a) of the Securities Exchange Act of 1934 relating to the attempted acquisition of Allergan by Valeant and its affiliates in 2014 in which certain Defendants traded on material non-public information relating to the proposed acquisition, which caused investors to sell call options and equity forward contracts at artificially deflated prices and purchase put options at artificially inflated prices.
About Kahn Swick & Foti, LLC
KSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
